Casaasdas

A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).

Por um escritor misterioso
Last updated 27 fevereiro 2025
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Monthly improvements in paid work productivity: ankylosing spondylitis
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
IJMS, Free Full-Text
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
New evidence on the management of spondyloarthritis
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
PDF) The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Oscar IRVIN-SELLERS, Medigene AG
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
WO2021067465A1 - Treating spondyloarthritic and psoriatic conditions with upadacitinib - Google Patents
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial - The Lancet
Recomendado para você
você pode gostar

© 2014-2025 radioexcelente.pe. All rights reserved.